We were able to use non-specialist equipment and freely available software to quantify the size and number of plaques, providing an indication as to whether drugs are able to interfere with α-synuclein aggregation, a promising disease-modifying approach for treatment of PD [36,38]. This evidence concerns the gene SNCA and Parkinson disease.